Release of fat and bone marrow during medullary pressurisation leads to fat embolism and pulmonary hypertension resulting in serious cardiorespiratory complications. This study aimed to determine whether pre-treatment with the phosphodiesterase type 5-inhibitor, Sildenafil, prevents pulmonary artery hypertension in an animal model. The animals either received Sildenafil (5 mg kg-1) or saline intra peritoneally 15 minutes prior to medullary pressurisation with bone cement. Cardiovascular parameters were recorded throughout the procedure. At the end radiopaque contrast was injected into the pulmonary circulation; the lungs were then harvested and imaged using micro CT. Medullary pressurisation in the control animals caused pulmonary hypertens...
The recruitment of bone marrow (BM)-derived progenitor cells to the lung is related to pulmonary rem...
Pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive inc...
Sildenafil, a selective and potent inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosp...
Release of fat and bone marrow during medullary pressurisation leads to fat embolism and pulmonary h...
ABSTRACT Background: Sudden, peri-operative cardiovascular deterioration ...
Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of pulmona...
Background: Sudden, intraoperative cardiovascular deterioration as a result of pulmonary embolizatio...
Selective pulmonary vasodilators attenuate acute pulmonary embolism (APE)-induced pulmonary hyperten...
Sildenafil, an oral phosphodiesterase Type 5 inhibitor, has vasodilatory effects through a cGMP-depe...
ABSTRACT: Statins have been proposed to be a potential treatment for pulmonary arterial hypertension...
Background: Hypoxia represents both an outcome of cardiopulmonary diseases and a trigger for severe ...
Chronic damage to pulmonary vessels leads to pulmonary hypertension (PH). Different forms of PH are ...
The therapy of pulmonary hypertension has evolved rapidly in the last 10 years from the use of non-s...
AbstractPulmonary arterial hypertension is defined as a group of diseases characterized by a progres...
BACKGROUND: The phosphodiesterase type-5 (PDE-5) inhibitor sildenafil has been reported to improve p...
The recruitment of bone marrow (BM)-derived progenitor cells to the lung is related to pulmonary rem...
Pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive inc...
Sildenafil, a selective and potent inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosp...
Release of fat and bone marrow during medullary pressurisation leads to fat embolism and pulmonary h...
ABSTRACT Background: Sudden, peri-operative cardiovascular deterioration ...
Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of pulmona...
Background: Sudden, intraoperative cardiovascular deterioration as a result of pulmonary embolizatio...
Selective pulmonary vasodilators attenuate acute pulmonary embolism (APE)-induced pulmonary hyperten...
Sildenafil, an oral phosphodiesterase Type 5 inhibitor, has vasodilatory effects through a cGMP-depe...
ABSTRACT: Statins have been proposed to be a potential treatment for pulmonary arterial hypertension...
Background: Hypoxia represents both an outcome of cardiopulmonary diseases and a trigger for severe ...
Chronic damage to pulmonary vessels leads to pulmonary hypertension (PH). Different forms of PH are ...
The therapy of pulmonary hypertension has evolved rapidly in the last 10 years from the use of non-s...
AbstractPulmonary arterial hypertension is defined as a group of diseases characterized by a progres...
BACKGROUND: The phosphodiesterase type-5 (PDE-5) inhibitor sildenafil has been reported to improve p...
The recruitment of bone marrow (BM)-derived progenitor cells to the lung is related to pulmonary rem...
Pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive inc...
Sildenafil, a selective and potent inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosp...